Amount of aggregate net sales attaining.

No definition available.

Name:	hrmy_AmountOfAggregateNetSalesAttaining
Namespace Prefix:	hrmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License agreement additional milestone payments due.

+ References

No definition available.

+ Details

Name:	hrmy_LicenseAgreementAdditionalMilestonePaymentsDue
Namespace Prefix:	hrmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

License agreement final payment paid.

+ References

No definition available.

+ Details

Name:	hrmy_LicenseAgreementFinalPaymentPaid
Namespace Prefix:	hrmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License agreement maximum additional milestone payments due.

+ References

No definition available.

+ Details

Name:	hrmy_LicenseAgreementMaximumAdditionalMilestonePaymentsDue
Namespace Prefix:	hrmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the amount of license agreement maximum additional milestone payments due upon achievement of development and regulatory milestones.

+ References

No definition available.

+ Details

Name:	hrmy_LicenseAgreementMaximumAdditionalMilestonePaymentsDueUponAchievementOfDevelopmentAndRegulatoryMilestones
Namespace Prefix:	hrmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the amount of license agreement maximum additional milestone payments due upon achievement of sales-based milestones.

+ References

No definition available.

+ Details

Name:	hrmy_LicenseAgreementMaximumAdditionalMilestonePaymentsDueUponAchievementOfSalesBasedMilestones
Namespace Prefix:	hrmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

License agreement milestone payments Due.

+ References

No definition available.

+ Details

Name:	hrmy_LicenseAgreementMilestonePaymentsDue
Namespace Prefix:	hrmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

License agreement milestone payments paid.

+ References

No definition available.

+ Details

Name:	hrmy_LicenseAgreementMilestonePaymentsPaid
Namespace Prefix:	hrmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents information pertaining to license agreement upfront fees paid.

+ References

No definition available.

+ Details

Name:	hrmy_LicenseAgreementUpfrontFeePaid
Namespace Prefix:	hrmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents information pertaining to license agreement upfront non-refundable fees paid.

+ References

No definition available.

+ Details

Name:	hrmy_LicenseAgreementUpfrontNonRefundableFeePaid
Namespace Prefix:	hrmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent License and asset purchase agreements.

+ References

No definition available.

+ Details

Name:	hrmy_LicenseAndAssetPurchaseAgreementsLineItems
Namespace Prefix:	hrmy_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Licensing agreement milestone fees

+ References

No definition available.

+ Details

Name:	hrmy_LicensingAgreementMilestoneFees
Namespace Prefix:	hrmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=hrmy_BioprojetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=hrmy_PitolisantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=hrmy_WAKIXMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=hrmy_Orexin2ReceptorAgonistOx2rMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=hrmy_UponAchievementOfAggregateNetSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS (Details) - Bioprojet - USD ($) $ in Thousands	1 Months Ended							12 Months Ended
	Dec. 31, 2025	Oct. 31, 2022	Mar. 31, 2022	Jan. 31, 2021	Oct. 31, 2020	Nov. 30, 2019	Aug. 31, 2019	Dec. 31, 2024	Apr. 30, 2024	Jul. 31, 2022	Feb. 28, 2019
License Agreements and Asset Purchase Agreements
Licensing agreement milestone fees							$ 2,000
License agreement milestone payments paid						$ 75,000	2,000
License agreement, additional milestone payment due							102,000
UNITED STATES
License Agreements and Asset Purchase Agreements
Amount of Aggregate Net Sales Attaining in US			$ 500,000
Upon Acceptance by FDA of Pitolisant's
License Agreements and Asset Purchase Agreements
License agreement, milestone payment due											$ 50,000
License agreement, upfront non-refundable licensing fees paid		$ 30,000
License agreement, maximum additional milestone payment due										$ 155,000
Upon FDA Approval of WAKIX
License Agreements and Asset Purchase Agreements
License agreement, milestone payment due							77,000
Licensing agreement milestone fees							$ 2,000
License agreement milestone payments paid				$ 100,000	$ 2,000
Orexin-2 receptor agonist (OX2R)
License Agreements and Asset Purchase Agreements
License agreement milestone payments paid	$ 4,250
Payment of upfront license fee								$ 25,500
Amount of fee payable upon achieving development and regulatory milestones									$ 123,250
Amount of fees payable upon achieving sale-based milestones									$ 240,000
Attaining $500,000 Aggregate Net Sales in US \| Upon FDA Approval of WAKIX \| UNITED STATES
License Agreements and Asset Purchase Agreements
Final payment paid			$ 40,000